论文部分内容阅读
目的：探讨女性原发性尿道癌组织中雌激素受体（ＥＲ）及癌相关基因ｃ－ｅｒｂＢ－２产物的表达及其与组织学分级、分型和预后的关系。方法：对３１例女性尿道癌组织用免疫组化ＬＳＡＢ法标记ＥＲ、ｃ－ｅｒｂＢ－２蛋白。结果：ＥＲ、ｃ－ｅｒｂＢ－２在女性尿道癌中阳性表达率分别为５１．６％、４５．２％，ＥＲ在高分化癌中阳性表达率较高，而ｃ－ｅｒｂＢ－２产物在中低分化癌中阳性表达率较高，ＥＲ以及ｃ－ｅｒｂＢ－２的表达与女性尿道癌组织学类型无明显关系（Ｐ＞０．０５），１６例有随访资料的病例中，ＥＲ阳性表达者５年生存病例为５／８多于ＥＲ阴性者（１／８）。结论：ＥＲ可作为女性尿道癌分化好，预后较佳的标志物之一，ｃ－ｅｒｂＢ－２的表达主要反映女性尿道癌的分化程度。
Objective: To investigate the expression of estrogen receptor (ER) and c-erbB-2 in female patients with primary urethral carcinoma and its relationship with histological grade, classification and prognosis. Methods: The ER and c-erbB-2 proteins were labeled by immunohistochemical LSAB in 31 cases of female urethral carcinoma. Results: The positive expression rates of ER and c-erbB-2 in female urethral carcinoma were 51.6% and 45.2%, respectively. The positive expression rate of ER was higher in well differentiated carcinoma than that in c-erbB-2 The positive expression rates of ER and c-erbB-2 were not significantly correlated with histological types of female urethral carcinoma (P> 0.05). Among the 16 cases with follow-up data, the positive expression rates of ER and c-erbB- Five-year survival was 5/8 more than ER-negative (1/8). Conclusion: ER can be used as one of the markers of well-differentiated and prognosis of female urethral carcinoma. The expression of c-erbB-2 mainly reflects the differentiation of female urethral carcinoma.